Insider Selling: PerkinElmer, Inc. (PKI) Insider Sells 2,324 Shares of Stock

PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,324 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $75.44, for a total transaction of $175,322.56. Following the completion of the sale, the insider now directly owns 8,876 shares in the company, valued at $669,605.44. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Andrew Okun also recently made the following trade(s):

  • On Monday, February 5th, Andrew Okun sold 2,273 shares of PerkinElmer stock. The shares were sold at an average price of $77.86, for a total transaction of $176,975.78.
  • On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The shares were sold at an average price of $72.00, for a total transaction of $912,960.00.

Shares of PerkinElmer, Inc. (NYSE:PKI) opened at $72.83 on Friday. PerkinElmer, Inc. has a 12 month low of $53.63 and a 12 month high of $84.49. The stock has a market cap of $8,027.69, a PE ratio of 24.94, a price-to-earnings-growth ratio of 1.68 and a beta of 0.76. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72.

PerkinElmer (NYSE:PKI) last released its quarterly earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.03. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The company had revenue of $641.63 million for the quarter, compared to analysts’ expectations of $619.14 million. During the same period last year, the company earned $0.83 EPS. The firm’s revenue for the quarter was up 13.2% compared to the same quarter last year. sell-side analysts predict that PerkinElmer, Inc. will post 3.52 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Shareholders of record on Friday, April 13th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $0.28 annualized dividend and a dividend yield of 0.38%. PerkinElmer’s dividend payout ratio is currently 10.61%.

Institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new stake in shares of PerkinElmer in the fourth quarter worth approximately $61,260,000. Koch Industries Inc. acquired a new stake in shares of PerkinElmer in the second quarter worth approximately $364,000. Assenagon Asset Management S.A. acquired a new stake in shares of PerkinElmer in the third quarter worth approximately $23,168,000. Robecosam AG boosted its position in shares of PerkinElmer by 165.7% in the third quarter. Robecosam AG now owns 477,167 shares of the medical research company’s stock worth $32,610,000 after acquiring an additional 297,595 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of PerkinElmer by 3.2% in the fourth quarter. BlackRock Inc. now owns 6,260,111 shares of the medical research company’s stock worth $457,740,000 after acquiring an additional 195,851 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

A number of equities research analysts recently commented on PKI shares. Robert W. Baird increased their price objective on shares of PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research note on Monday, January 8th. Morgan Stanley increased their price objective on shares of PerkinElmer from $77.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. Jefferies Group reissued a “hold” rating and issued a $70.00 price objective on shares of PerkinElmer in a research note on Friday, October 20th. Finally, Cowen reissued a “hold” rating and issued a $84.00 price objective on shares of PerkinElmer in a research note on Friday, January 26th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $76.85.

COPYRIGHT VIOLATION WARNING: “Insider Selling: PerkinElmer, Inc. (PKI) Insider Sells 2,324 Shares of Stock” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.com-unik.info/2018/02/11/insider-selling-perkinelmer-inc-pki-insider-sells-2324-shares-of-stock.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit